Wall Street analysts expect Acadia Pharmaceuticals (NASDAQ:ACAD) to announce ($0.56) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Acadia Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.57) and the highest is ($0.53). Acadia Pharmaceuticals reported earnings of ($0.72) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 22.2%. The company is expected to issue its next quarterly earnings report on Tuesday, May 8th.
On average, analysts expect that Acadia Pharmaceuticals will report full-year earnings of ($1.82) per share for the current financial year, with EPS estimates ranging from ($2.00) to ($1.63). For the next financial year, analysts forecast that the business will post earnings of ($0.73) per share, with EPS estimates ranging from ($1.26) to ($0.31). Zacks’ earnings per share averages are an average based on a survey of analysts that cover Acadia Pharmaceuticals.
Acadia Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.03. Acadia Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 231.71%. The firm had revenue of $43.56 million for the quarter, compared to analyst estimates of $45.30 million.
In other Acadia Pharmaceuticals news, EVP Glenn Baity sold 36,558 shares of the company’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $32.39, for a total value of $1,184,113.62. Following the completion of the transaction, the executive vice president now owns 83,734 shares in the company, valued at approximately $2,712,144.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Daniel B. Soland acquired 7,000 shares of Acadia Pharmaceuticals stock in a transaction on Thursday, March 1st. The stock was acquired at an average price of $23.91 per share, with a total value of $167,370.00. Following the purchase, the director now directly owns 2,000 shares in the company, valued at $47,820. The disclosure for this purchase can be found here. 22.25% of the stock is owned by corporate insiders.
A number of large investors have recently made changes to their positions in the business. Earnest Partners LLC purchased a new position in shares of Acadia Pharmaceuticals during the 4th quarter valued at $133,000. Ladenburg Thalmann Financial Services Inc. lifted its position in shares of Acadia Pharmaceuticals by 56.8% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,509 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 2,358 shares during the last quarter. Steward Partners Investment Advisory LLC purchased a new position in shares of Acadia Pharmaceuticals during the 4th quarter valued at $200,000. State of Alaska Department of Revenue purchased a new position in shares of Acadia Pharmaceuticals during the 4th quarter valued at $219,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Acadia Pharmaceuticals by 30.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,403 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 1,733 shares during the last quarter. Hedge funds and other institutional investors own 96.24% of the company’s stock.
Shares of ACAD opened at $19.66 on Tuesday. Acadia Pharmaceuticals has a 52-week low of $15.74 and a 52-week high of $41.20. The company has a market capitalization of $2,491.54, a price-to-earnings ratio of -8.33 and a beta of 3.43.
Acadia Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acadia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.